Safdar Amar, Chaturvedi Vishnu, Koll Brian S, Larone Davise H, Perlin David S, Armstrong Donald
Infectious Diseases Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York, USA.
Antimicrob Agents Chemother. 2002 Oct;46(10):3268-72. doi: 10.1128/AAC.46.10.3268-3272.2002.
Since the 1990s, the substantial increase in the rate of Candida glabrata infections has become a serious problem. As most C. glabrata infections arise from the host's endogenous microflora, the present prospective, multicenter analysis included all clinical isolates associated with colonization and with systemic and hematogenous candidiasis. Among 347 C. glabrata isolates, the overall rates of resistance to fluconazole (MIC > or = 64 micro g/ml) and itraconazole (MIC > or = 1 micro g/ml) were 10.7 and 15.2%, respectively, although for half (n = 148) of the itraconazole-susceptible isolates the MICs (0.25 to 0.5 micro g/ml) were in the susceptible-dependent upon dose range. Fluconazole resistance was more common among C. glabrata isolates obtained from centers caring for patients with cancer (MICs at which 90% of isolates are inhibited [MIC(90)s] = 32 micro g/ml) or AIDS (MIC(90)s > 64 micro g/ml) than among C. glabrata isolates from a community-based university medical center (MIC(90)s = 16 micro g/ml) (P = 0.001). Thirty-three bloodstream isolates and those obtained from other body sites had similar in vitro susceptibility profiles. The fluconazole MIC(90)s (< or =16 micro g/ml) for C. glabrata yeast isolates from the gastrointestinal tract were lower than those (> or =64 micro g/ml) for C. glabrata isolates from respiratory and urinary tract samples (P = 0.01). A similar discrepancy for itraconazole was not significant (P > 0.5). We did not observe differences in fluconazole or itraconazole susceptibility profiles among C. glabrata isolates associated with either hematogenous dissemination or colonization. The significant discrepancy in antifungal susceptibility among C. glabrata organisms isolated from hospitals in the same geographic region emphasizes the significance of periodic susceptibility surveillance programs for individual institutions, especially those providing care to patients at risk.
自20世纪90年代以来,光滑念珠菌感染率的大幅上升已成为一个严重问题。由于大多数光滑念珠菌感染源于宿主的内源性微生物群,因此本前瞻性多中心分析纳入了所有与定植以及系统性和血源性念珠菌病相关的临床分离株。在347株光滑念珠菌分离株中,对氟康唑(MIC≥64μg/ml)和伊曲康唑(MIC≥1μg/ml)的总体耐药率分别为10.7%和15.2%,不过对于一半(n = 148)伊曲康唑敏感的分离株,其MIC(0.25至0.5μg/ml)处于剂量依赖性敏感范围内。在从癌症患者护理中心(90%分离株被抑制时的MIC[MIC(90)s]=32μg/ml)或艾滋病患者护理中心(MIC(90)s>64μg/ml)分离得到的光滑念珠菌中,氟康唑耐药比在社区大学医学中心分离得到的光滑念珠菌(MIC(90)s = 16μg/ml)更为常见(P = 0.001)。33株血流分离株以及从其他身体部位获得的分离株具有相似的体外药敏谱。来自胃肠道的光滑念珠菌酵母分离株的氟康唑MIC(90)s(≤16μg/ml)低于来自呼吸道和泌尿道样本的光滑念珠菌分离株的氟康唑MIC(90)s(≥64μg/ml)(P = 0.01)。伊曲康唑的类似差异不显著(P>0.5)。我们未观察到与血行播散或定植相关的光滑念珠菌分离株在氟康唑或伊曲康唑药敏谱方面存在差异。在同一地理区域的医院分离得到的光滑念珠菌生物体之间抗真菌药敏的显著差异强调了针对各个机构,尤其是为高危患者提供护理的机构进行定期药敏监测计划的重要性。